Posted by Michael Wonder on 23 Dec 2017
Institute for Clinical and Economic Review's final report on VMAT2 inhibitors for tardive dyskinesia calls for manufacturer and payer action to lower prices and assure adequate access
22 December 2017 - Evidence suggests drugs offer short-term benefits but are vastly overpriced, leading to “low value” designation and triggering ICER’s Affordability and Access Alert.
The Institute for Clinical and Economic Review today released a final evidence report and Report-at-a-Glance on vesicular monoamine transporter 2 (VMAT2) inhibitors for management of tardive dyskinesia.
The report reviews evidence on the comparative clinical effectiveness and value of valbenazine (Ingrezza, Neurocrine Biosciences, Inc.), deutetrabenazine (Austedo, Teva), and tetrabenazine (Xenazine, Lundbeck and multiple generics).
